ADIENNE Pharma & Biotech is focused on developing innovative biopharmaceutical solutions, particularly for orphan diseases where treatment options are limited. The company has established a proprietary portfolio that includes both marketed medicinal products and candidates in various stages of clinical and preclinical development. A significant aspect of their technology is the development of a unique ready-to-use delivery system for cytotoxic drugs, specifically through their patented lyophilization method. This system is designed to enhance safety and ease of use for healthcare professionals, allowing for the administration of treatments in both clinical settings and at home, thereby improving patient access to necessary therapies.

The company has received multiple authorizations from regulatory bodies, including the European Medicines Agency (EMA) and the Italian Medicines Agency (AIFA), which validate their manufacturing capabilities and the quality of their products. Notably, ADIENNE's facility in Caponago, Italy, is authorized to produce a range of formulations, including large volume liquids and lyophilized cytotoxic products. Their innovative approach not only addresses compliance issues associated with cytotoxic drug handling but also opens new therapeutic avenues, particularly in the treatment of acute graft-versus-host disease (aGvHD) through their monoclonal antibody product. This commitment to advancing biopharmaceutical technologies positions ADIENNE as a key player in addressing high unmet medical needs.

Switzerland


ADIENNE is an integrated biopharmaceutical group of companies based in Lugano, Switzerland, with a proprietary portfolio of orphan-designated marketed medicinal product, clinical and preclinical product candidates focusing on critical conditions of high unmet medical needs.

ADIENNE Pharma & Biotech

Company Details